Journal of the National Comprehensive Cancer Network · 2019 · 1.6K citations · 229 references
MedicineOncologyUrologyGenitourinary OncologyMolecular OncologyUrologic OncologyAndrogen Deprivation TherapyBiomarkers In Genitourinary CancerProstate BiopsyProstate CancerProstate PathologyProstate-specific Antigen TestingCombination Hormonal TherapyGenetic TestingGenomic Risk StratificationLocalized Disease AssessmentMolecular Tumor ClassificationProstate Cancer DiagnosisProstate Cancer Hormone TherapyProstate Cancer Risk Stratification
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
229
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations
Life Sciences, Immunology, Oncology +17
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text